Guggenheim has initiated its coverage of psychedelic drug developer Cybin (NYSE:CYBN) with a Buy rating and a $35 per share ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...

Spravato (esketamine) has possible interactions with alcohol, some other drugs, and certain supplements. Examples include Adderall and benzodiazepines such as clonazepam (Klonopin). Talk with your ...

Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...

Ketamine advertisements are popping up all around us. With few regulations in place, might we be witnessing another opioid epidemic?

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...

Living Local 15 host Jessica Williams is joined by Sean Goddard, a Psychiatric Nurse Practitioner and Owner of Viking Psychiatry, to speak about the recent approval for Spravato as a monotherapy ...

Stella Mental Health Westmont is a top depression and anxiety clinic near Chicago that offers comprehensive mental health treatments like Spravato (esketamine) therapy, ketamine infusion ...

Johnson & Johnson (NYSE:JNJ) is currently addressing shareholder proposals regarding executive compensation and human rights ...